What is XcellaraHeart™ and how is it related to BDPT's Xcellara™ platform?

XcellaraHeart™ is the first targeted formula built on the Xcellara™ platform, focused on cardiovascular wellness goals. According to BioAdaptives, it combines the Xcellara™ base with Tanshinone IIA, a compound studied in relation to SDF-1α/CXCR4 signaling and cardiovascular repair.

BioAdaptives Explains the Scientific Basis of the Dual-Action Xcellara(TM) "Supply and Direction" Platform

Rhea-AI Impact

(Very High)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

BioAdaptives (OTC:BDPT) outlined the scientific basis of its Xcellara™ “Supply and Direction” supplement platform, which combines clinically researched stem/progenitor cell mobilization with ingredients studied for tissue signaling pathways. The proprietary base formulation was evaluated in a randomized, double-blind, placebo-controlled human trial and showed an average 268.8% increase in circulating primitive stem/progenitor-type cells after four weeks, with no adverse effects across more than 20 blood parameters, according to the company.

The “Supply” component focuses on raising measurable circulating stem and progenitor cells, while the “Direction” component adds natural compounds selected from published research on pathways such as the SDF-1α/CXCR4 chemokine axis. XcellaraHeart™, featuring Tanshinone IIA for cardiovascular-focused signaling support, is the first commercial product from this platform. BioAdaptives plans additional Xcellara™ formulas for joint, neurological, skin and other wellness targets, all built on the same clinically studied base plus tissue-specific signaling ingredients.

Positive

Human clinical trial showed a 268.8% rise in circulating hematopoietic stem and progenitor cells after four weeks
No adverse effects reported on more than 20 measured blood parameters in the clinical trial
Platform model supports multiple targeted wellness products (cardiac, joint, neural, dermal, longevity, stress) from a single validated base
First commercial product XcellaraHeart™ launched using the dual-action Supply and Direction platform

Negative

None.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

08/04/2026 - 08:00 AM

The Platform integrates clinically researched stem and progenitor cell mobilization with ingredients that have been studied for their roles in tissue signaling pathways.

LAS VEGAS, NV / ACCESS Newswire / August 4, 2026 / A developer of natural, science-backed wellness solutions today explained the scientific basis for its Xcellara^™ "Supply and Direction" product development platform.

Traditional stem cell support products mainly aim to boost circulating stem cell levels in the blood. While this offers certain health benefits, it does not guide the mobilized cells to specific target areas. On the other hand, typical tissue support ingredients like joint collagen or heart supplements often lack enough active stem cells for effective structural repair. BioAdaptives' Xcellara^™ platform addresses this issue by merging two biological phases into a single, unified formulation.

For years, the cellular wellness industry faced a **'So What?'** problem: although increasing circulating stem cells was achievable, there was no guarantee they would reach the target areas, explained James Keener, CEO of BioAdaptives. "Our Xcellara platform is designed to integrate a clinically proven mobilization base with ingredients selected based on published research on tissue-related signaling pathways. XcellaraHeart^™ is the first commercial product resulting from this development approach."

Phase 1: Supply - Stem/Progenitor Cell Mobilization

All Xcellara^™ platform products are based on a proprietary core formulation that was tested in a randomized, double-blind, placebo-controlled human clinical trial. In this study, the formulation showed an average increase of 268.8% in circulating primitive stem/progenitor-type cells after four weeks. Additionally, the trial observed no adverse effects across more than 20 measured blood parameters.

BioAdaptives considers these findings a solid scientific basis for the "Supply" component of the platform, which focuses on increasing the measurable presence of circulating stem and progenitor cells that support the body's natural maintenance functions.

Phase 2: Direction - Tissue-Associated Signaling Support

The "Direction" component combines the clinically studied Xcellara^™ base with natural compounds known to influence signaling pathways in specific tissues and for wellness goals. One such pathway is the SDF-1α/CXCR4 chemokine axis, which plays a role in cellular migration and trafficking.

XcellaraHeart^™ is the first targeted formula developed on the platform, featuring Tanshinone IIA, a natural compound derived from Danshen. Preclinical studies have examined Tanshinone IIA's role in SDF-1α/CXCR4 signaling and cardiovascular repair. This research supports its inclusion in XcellaraHeart^™.

Keener explains that the model is called 'Supply and Direction' because it makes the science understandable. 'Supply' refers to human clinical evidence showing increased circulating stem and progenitor cells. 'Direction' uses published pathway research to select additional ingredients for targeted wellness goals. Together, these elements form a structured, repeatable process for expanding the Xcellara product line.

BioAdaptives views the dual-component platform as the foundation for a series of targeted cellular-wellness products. In addition to XcellaraHeart^™, the Company is developing new Xcellara^™ products for joint and cartilage support, neurological wellness, skin health, and other targeted wellness applications. Each prospective formula will combine the clinically studied Xcellara^™ base with ingredients selected based on published research relevant to the intended wellness category.

The Company's scientific dossier, including information on the human clinical trial, principal ingredients, and relevant signaling-pathway research, is available at https://practitioners.xcellara.com.

About BioAdaptives, Inc.
BioAdaptives^® Inc. develops the Xcellara^™ line of supplements that promote stem cell mobilization and tissue targeting. Its flagship product, the Xcellara^™ base formula, is the only dietary supplement backed by a human randomized, double-blind, placebo-controlled clinical trial showing a 268.8% rise in circulating hematopoietic stem and progenitor cells after four weeks, with no negative effects on over twenty blood parameters. The product line features seven specialized formulas that combine this clinically validated mobilization base with tissue-specific signaling ingredients for cardiac, joint, neural, dermal, longevity, and stress resilience uses. More details are available at products.xcellara.com.

Regulatory Disclaimer

These statements have not been evaluated by the Food and Drug Administration. XcellaraHeart^™, MyndSystem^™, MyndMed^™, and MyndRenew^™ are not intended to diagnose, treat, cure, or prevent any disease. Xcellara^™ is a trademark of BioAdaptives^® Inc.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding product positioning, intended benefits, market opportunity, and future business strategy. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. BioAdaptives undertakes no obligation to update these statements except as required by law.

INVESTOR & MEDIA CONTACT
Emily Harrison
EHarrison@BioAdaptives.com
BioAdaptives, Inc.
702-659-8829
X - @BioAdaptivesInc

BioAdaptives^® Inc.
2620 Regatta Dr
Suite 102
Las Vegas, NV 89128
www.bioadaptives.com
products.xcellara.com

https://practitioners.xcellara.com

SOURCE: BioAdaptiveas, Inc.

View the original press release on ACCESS Newswire

FAQ

What is BioAdaptives (BDPT) Xcellara™ "Supply and Direction" platform?

Xcellara™ is a dual-action supplement platform that combines stem/progenitor cell mobilization with tissue-specific signaling support. According to BioAdaptives, it uses a clinically studied core formula plus targeted ingredients chosen from published pathway research for defined wellness goals.

What did the Xcellara™ human clinical trial show for BDPT?

The human trial of the Xcellara™ base reported a 268.8% average increase in circulating primitive stem/progenitor-type cells after four weeks. According to BioAdaptives, more than 20 blood parameters showed no adverse effects during this randomized, double-blind, placebo-controlled study.

How does the Xcellara™ platform support targeted wellness products for BioAdaptives (BDPT)?

The platform uses a clinically validated mobilization base as the "Supply" component, then adds ingredients chosen for tissue-related signaling pathways as the "Direction" component. According to BioAdaptives, this creates a repeatable process to build cardiac, joint, neural, dermal and other wellness formulas.

What future Xcellara™-based products is BioAdaptives (BDPT) developing?

BioAdaptives is developing new Xcellara™ formulations for joint and cartilage support, neurological wellness, skin health and other wellness uses. According to BioAdaptives, each candidate combines the clinically studied base with signaling ingredients relevant to the intended wellness category.

Are XcellaraHeart™ and other BDPT Xcellara™ products FDA-evaluated or disease treatments?

According to BioAdaptives, statements about these products have not been evaluated by the FDA, and XcellaraHeart™, MyndSystem™, MyndMed™ and MyndRenew™ are not intended to diagnose, treat, cure or prevent any disease. They are positioned as dietary supplements for wellness support.